Section Arrow
Quote
RIGL.NASDAQ
- Rigel Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/11/04 14:31 EST
Regular Hours
Last
 51.15
+2.29 (+4.69%)
Day High 
51.7399 
Prev. Close
48.86 
1-M High
52.605 
Volume 
128.43K 
Bid
51.05
Ask
51.24
Day Low
49.225 
Open
50.57 
1-M Low
45.22 
Market Cap 
912.70M 
Currency 美元 
P/E 2.89 
%Yield -- 
10-SMA 49.92 
20-SMA 48.79 
50-SMA 47.86 
52-W High 52.605 
52-W Low 24.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
16.89/5.26
Enterprise Value
935.58M
Balance Sheet
Book Value Per Share
22.77
Cash Flow
Cash Flow Yield
0.08
Income Statement
Total Revenue
294.28M
Operating Revenue Per Share
7.09
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.235+0.5211+72.99%0.2PE
KPTIKaryopharm Therapeutics Inc.0.0851-0.0032-3.62%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.655-0.005-0.30%-- 
NRIXNurix Therapeutics16.31-9.51-36.83%10.63PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.